“Efficacy and Safety of Risankizumab in Patients With Erythrodermic and Sub-Erythrodermic Psoriasis: A Case Series”. Dermatology Reports (July 30, 2025). Accessed August 4, 2025. https://journals.pagepress.org/dr/article/view/10379.